[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on Chinese Ioversol Market, 2018-2022

July 2018 | 30 pages | ID: I31F0167CE9EN
China Research and Intelligence Co., Ltd.

US$ 2,200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Description

Contract media are chemical products that are injected into or taken by human tissues or organs to improve image observation. The global contrast media market is growing continuously with higher demand for medical exam accuracy and increasing popularity of angiography.

Ioversol is a new-type non-ionic contrast agent mainly used in contrast-enhanced vascular imaging, featured by high contract density, avirulence, high tolerance and few side effects. After Ioversol is injected to blood vessels, the high proportion of iodine can cause x-ray attenuation and clearly show the blood vessels till Ioversol is diluted.

Contrast media are among the most common drugs in interventional radiology practice. They are mainly used to show blood vessels and coeloms. With large growth momentum and potential, the applications of contrast media have gradually extended from x-ray photography/CT scan imaging to diagnoses and examinations such as ultrasonography and magnetic resonance angiography. Ioversol has been widely used in China. As the number of the diagnosed continues to rise, the Ioversol market will continue to grow in China.

With China's growing demand for Ioversol, the sales value exceeded CNY 400 million in 2017. According to CRI, Jiangsu Hengrui, Liebel-Flarsheim and Mallinckrodt accounted for the major shares of the Chinese Ioversol market. By sales value, the market share of Jiangsu Hengrui exceeded 90% in 2017.

Topics Covered:
  • Development history of Ioversol in China
  • Size of China Ioversol market
  • Competition Pattern of Chinese Ioversol market
  • Prices in the Chinese Ioversol market
  • Prospects of Chinese Ioversol Market, 2018-2022
1 RELEVANT CONCEPTS OF IOVERSOL

1.1 Indications
1.2 Development History of Ioversol in China
1.3 Production Permit of Ioversol in China

2 INVESTIGATION ON SALES OF IOVERSOL IN CHINA, 2013-2017

2.1 Sales Value of Ioversol in China
  2.1.1 Overall Sales Value
  2.1.2 Sales Value in Different Regions
2.2 Sales Volume of Ioversol in China
  2.2.1 Overall Sales Volume
  2.2.2 Sales Volume in Different Regions
2.3 Sales of Ioversol in Different Dosage Forms in China
  2.3.1 Market Share of Ioversol in Different Dosage Forms by Sales Value
  2.3.2 Market Share of Ioversol in Different Dosage Forms by Sales Volume

3 INVESTIGATION ON MARKET SHARE OF MAJOR IOVERSOL MANUFACTURERS IN CHINA, 2013-2017

3.1 Analysis on Market Competition of Ioversol in China, 2013-2017
  3.1.1 Major Manufacturers
  3.1.2 Market Share by Sales Value
  3.1.3 Market Share by Sales Volume
3.2 Jiangsu Hengrui Medicine Co., Ltd.
  3.2.1 Profile of Jiangsu Hengrui Medicine Co., Ltd.
  3.2.2 Sales of Jiangsu Hengrui's Ioversol
  3.2.3 Sales Price of Jiangsu Hengrui's Ioversol
3.3 Liebel-Flarsheim
3.4 Mallinckrodt

4 PROSPECTS OF CHINESE IOVERSOL MARKET, 2018-2022

4.1 Forecast on Market Size
4.2 Forecast on Competition Pattern

SELECTED CHARTS

Chart Production Permit of Ioversol in China
Chart Sales of Ioversol in China
Chart Sales Value of Ioversol in China, 2007-2017
Chart Sales Value of Ioversol in Parts of China, 2013-2017
Chart Sales Volume of Ioversol in China, 2007-2017
Chart Sales Volume of Ioversol in Parts of China, 2013-2017
Chart Market Share and Sales Value of Jiangsu Hengrui's Ioversol in China, 2013-2017
Chart Market Share and Sales Value of Liebel-Flarsheim's Ioversol in China, 2013-2017
Chart Market Share and Sales Value of Mallinckrodt's Ioversol in China, 2013-2017
Chart Sales Value and Market Share of Ioversol Injections in China, 2013-2017
Chart Prices of Jiangsu Hengrui's Ioversol in Several Chinese Cities, 2017-2018
Chart Prices of Mallinckrodt's Ioversol in Several Chinese Cities, 2017-2018
Chart Forecast on Ioversol's Sales in China, 2018-2022


More Publications